About
Thytech develops innovative cell therapies based on regulatory T cells purified from pediatric thymus tissue to treat serious immunological and inflammatory disorders, focusing initially on preventing rejection in pediatric heart transplantation.
Explore Thytech's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.